Wealth Enhancement Advisory Services LLC lessened its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 7.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,419 shares of the financial services provider’s stock after selling 2,643 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.06% of iShares Biotechnology ETF worth $4,720,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of IBB. Ashton Thomas Private Wealth LLC increased its holdings in iShares Biotechnology ETF by 50.9% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 5,291 shares of the financial services provider’s stock worth $726,000 after acquiring an additional 1,784 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of iShares Biotechnology ETF by 16.9% in the first quarter. Sequoia Financial Advisors LLC now owns 2,409 shares of the financial services provider’s stock worth $331,000 after buying an additional 349 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in iShares Biotechnology ETF by 25.7% during the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after buying an additional 420,053 shares during the period. Connecticut Wealth Management LLC grew its position in iShares Biotechnology ETF by 7.0% during the first quarter. Connecticut Wealth Management LLC now owns 9,015 shares of the financial services provider’s stock worth $1,237,000 after buying an additional 590 shares in the last quarter. Finally, Westwood Wealth Management raised its holdings in shares of iShares Biotechnology ETF by 48.2% in the 1st quarter. Westwood Wealth Management now owns 12,475 shares of the financial services provider’s stock valued at $1,712,000 after acquiring an additional 4,060 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Trading Down 1.5 %
Shares of IBB opened at $140.29 on Friday. The stock has a 50-day moving average price of $145.24 and a 200-day moving average price of $140.27. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.57.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Dividend Payout Ratio Calculator
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What is the S&P/TSX Index?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.